Related Experiment Videos
Clonidine suppression test--an evaluation of its diagnostic significance in hypertensive patients
Insights
The Clonidine Suppression Test (CST) effectively diagnoses pheochromocytoma by showing suppressed plasma catecholamine levels in healthy individuals and those with essential hypertension, unlike in pheochromocytoma patients. This test is safe and reliable for identifying this adrenal tumor.
Area of Science:
- Endocrinology
- Clinical Diagnostics
Background:
- Pheochromocytoma diagnosis can be challenging.
- Hypertension management requires accurate etiological diagnosis.
Purpose of the Study:
- To evaluate the efficacy of the Clonidine Suppression Test (CST) in diagnosing pheochromocytoma.
- To assess plasma catecholamine (CA) levels in response to clonidine in various hypertensive groups.
Main Methods:
- The Clonidine Suppression Test (CST) was administered to patients with labile hypertension, essential hypertension (mild, moderate, severe), and pheochromocytoma.
- Plasma catecholamine (norepinephrine and epinephrine) levels were measured using a spectrofluorimetric method before and after clonidine administration.
- Blood pressure and heart rate were monitored throughout the test.
Main Results:
- Plasma catecholamine levels significantly decreased in patients with labile and essential hypertension after clonidine administration.
- In contrast, plasma catecholamine levels did not significantly fall and sometimes increased in patients with pheochromocytoma during the CST.
- Post-operative testing in pheochromocytoma patients showed normal catecholamine suppression, and no serious side effects were observed.
Conclusions:
- The Clonidine Suppression Test (CST) is a safe and reliable diagnostic tool for pheochromocytoma.
- The differential response of plasma catecholamines to clonidine distinguishes pheochromocytoma from other hypertensive conditions.
Abstract:
The Clonidine Suppression Test (CST) was performed in 8 patients with Labile hypertension (Group I), 8 patients with mild and moderate Essential hypertension (Group IIa), 8 patients with severe Essential hypertension (Group IIb) and 6 patients with pheochromocytoma (Group III). The mean plasma catecholamine (CA) levels as estimated by a Spectrofluorimetric method were significantly reduced 3-4 hours after administration of clonidine (5 micrograms/kg) by mouth in Group I, IIa & IIb patients. Plasma norepinephrine levels fell from 1.82 +/- SEM 0.35 ng/ml to 1.03 +/- 0.11 ng/ml (p less than 0.05) in Group I, 1.64 +/- 0.36 ng/ml to 0.88 +/- 0.12 ng/ml (p less than 0.025) in Group IIa, 1.23 +/- 0.16 ng/ml to 0.86 +/- 0.12 ng/ml (p less than 0.005) in Group IIb patients. Plasma epinephrine levels fell from 0.35 +/- 0.06 ng/ml to 0.16 +/- 0.03 ng/ml (p less than 0.05) in Group I, 0.34 +/- 0.04 ng/ml to 0.22 +/- 0.03 ng/ml (p less than 0.01) in Group IIa, 0.33 +/- 0.06 ng/ml to 0.18 +/- 0.03 ng/ml (p less than 0.025) in Group IIb patients. The blood pressure and heart rate showed a similar response. By contrast, in patients with pheochromocytoma, the mean plasma CA levels did not show any significant fall, and even rose during the CST, but, when repeated post-operatively, showed normal suppression. No serious side effects were noticed. We conclude that the CST is a safe and reliable test for the diagnosis of pheochromocytoma.(ABSTRACT TRUNCATED AT 250 WORDS)